Person: GÖREN, MEHMET ZAFER
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
GÖREN
First Name
MEHMET ZAFER
Name
14 results
Search Results
Now showing 1 - 10 of 14
Publication Open Access The effects of partial bilateral lesioning of substantia nigra in a genetic absence epilepsy rat model(2002-04-01) GÜLHAN, REZZAN; ONAT, FİLİZ; GÖREN, MEHMET ZAFER; GÖREN M. Z., GÜLHAN R., ONAT F., Ergün A.Objective: \"Genetic Absence Epilepsy Rats from Strasbourg\" (GAERS), an inbred Wistar strain, serve as an experimental venue. These rats generate spontaneous spike-and-wave discharges (SWD) and have increased γ-aminobutyric acid (GABA) levels in the ventrolateral thalamus (VLT). Recently, substantia nigra pars reticulata (SNpr) was reported to act as an endogeneous inhibitory mechanism in the generation, onset and maintenance of various types of seizures. The presence of tonic control exerted by SNpr in absence seizures should also be tested in GAERS. Methods: In this current study, GABA and L-glutamic acid release in VLT of GAERS with partial bilateral electrolytic lesions of SNpr was evaluated by using microdialysis technique with fluorescent detection. Results: GABA levels in VLT were 0.12±0.04 μM and 0.24±0.08 μM in sham-lesioned and SNpr-lesioned GAERS, respectively. L-glutamic acid level was found to be 0.41 5±0.150 μM in sham-lesioned group and 0.324±0.094 μM in SNpr-lesioned GAERS. Statistical analysis revealed no significant difference between sham-lesioned and SNpr-lesioned rats. The number and the duration of SWD were also similar in two groups. Conclusion: These findings show that SNpr does not exert a tonic control in GAERS and we assume that intact SNpr acts as a site that may exert an inhibition on target structures when activated in GAERS.Publication Open Access The α2C-adrenoceptor antagonist JP-1302 controls behavioral parameters, tyrosine hydroxylase activity and receptor expression in a rat model of ketamine-induced schizophrenia-like deficits(2022-11-01) AKAKIN, DİLEK; GÖREN, MEHMET ZAFER; Tekin N., Karamahmutoğlu T. E. , Aykaç A., AKAKIN D., GÖREN M. Z.© 2022Schizophrenia is a chronic disabling disease affecting 1 % of the population. Current antipsychotics have limited efficacy in mitigating the severity of the symptoms of the disease. Therefore, searching for new therapeutic targets is essential. Previous studies have shown that α2C-adrenoceptor antagonists may have antipsychotic and pro-cognitive effects. Therefore, the current study evaluates the behavioral and neurochemical effects of JP-1302, a selective α2C-adrenoceptor antagonist, in a model of schizophrenia-like deficits induced by sub-chronic ketamine (KET) administration. Here, we administered ketamine (25 mg/kg, i.p.) to male and female Wistar rats for eight consecutive days. On the last two days of ketamine administration, rats were pretreated with either JP-1302 (1-3-10 μmol/kg, i.p.), chlorpromazine (0.1 mg/kg, i.p.), or saline, and the behavioral tests were performed. Behaviors related to positive (locomotor activity), negative (social interaction), and cognitive (novel object recognition) symptoms of schizophrenia were assessed. Glutamate, glutamine, GABA levels, and α2C-adrenoceptor expression were measured in the frontal cortex and the hippocampus. Tyrosine hydroxylase immunocytochemical reactivity was also shown in the midbrain regions. Sub-chronic ketamine administration increased locomotor activity and produced robust social interaction and object recognition deficits, and JP-1302 significantly ameliorated ketamine-induced cognitive deficits. Ketamine induced a hyperdopaminergic activity in the striatum, which was reversed by the treatment with JP-1302. Also, the α2C-adrenoceptor expression was higher in the frontal cortex and hippocampus in the ketamine-treated rats. Our findings confirm that α2C-adrenoceptor antagonism may be a potential drug target for treating cognitive disorders related to schizophrenia.Publication Open Access Plasma concentration-time profile of a single dose of enteric-coated omeprazole in male and female healthy volunteers(2000-01-01) GÖREN, MEHMET ZAFER; AKIN, ŞEHNAZ; GÜLHAN, REZZAN; ONAT, FİLİZ; Iskender E., ASLAN N., GÖREN M. Z., Tellioglu T., Akin S., Erin N., GÜLHAN R., ONAT F., Berkman K., Oktay S.O b je c tiv e : T h e b io a vaila b ility of a single dose (20 m g) o f tw o e n te ric -c o a te d o m e p ra z o le fo rm u la tio n s, m arketed in T urkey, given 10-15 m in b e fo re b reakfast, w as studied in 12 healthy vo lu n te e rs (6 m ales and 6 fem ales) in a d o u b le blind, cro s s o v e r design. M e th o d s : B lood sam ples w ere collected prior to and at 10 tim e points w ithin 12 hrs. after dosing. P la s m a o m e p ra z o le c o n c e n tra tio n s w e re m easured by H P LC te ch n iq u e in our laboratory. R e s u lts a n d C o n c lu s io n s : T he tw o products w ere found to be b io e q u iva le n t in term s of extent of a b s o rp tio n (th e a re a u n d e r the p la s m a c o n c e n tra tio n -tim e cu rve s). M u ltip e a k p la sm a co n ce n tra tio n pro file s w e re seen in m ost of the su b je cts w ith both products. T im e to the e a rlie r peaks w as 1-2 hrs. and those peaks w ere low er in a m p litu d e th a n th e p e a ks re a ch e d a p p ro x im a te ly 4 .5 hrs. a fte r the a p p lica tio n . In te re stin g ly, the m u ltip e a k profile w as m ore fre q u e n t and the e a rlie r peaks w ere sig nificantly higher in fe m a le su b je cts than in m ales. The reason fo r th is g e n d e r d iffe re n ce in m ultipeak p la s m a c o n c e n tra tio n - tim e p ro file of oral o m e p ra zo le needs fu rth e r investigation.Publication Metadata only Kokain(Akademisyen Yayınevi Kitabevi, 2021-09-01) GÖREN, MEHMET ZAFER; Gören M. Z.Publication Metadata only Studies on Some 3-Oxo-5-benzylidene-6-methyl-(4H) -2-substitutedpyridazines with Antinociceptive and Antiinflammatory Activities(2003-03-01) GÖREN, MEHMET ZAFER; Balkan A., Özkanli F., ÜNSAL TAN O., GÖREN M. Z., TERZİOĞLU BEBİTOĞLU B.In this study, some new 3-oxo-5-benzylidene-6-methyl-(4H)-2-substituted pyridazine derivatives have been prepared by the reaction of 5-substituted benzylidene-6-methyl-(4H)-pyridazin-3-one with several substituted benzoyl-methyl bromides. The structures of the compounds have been elucidated by IR, 1H-NMR and elemental analysis. Antinociceptive (only for compound IIIa) and anti-inflammatory activity studies were evaluated by using in vivo tests. The anti-inflammatory activity was studied by means of the \"carrageenan paw edema\", whereas the \"acetic acid writhing\" test was used to assess the antinociceptive activity. Qualitatively, compound IIIa was shown to exert anti-inflammatory effect as potent as phenylbutazone and antinociceptive effect similar to acetylsalicylic acid.Publication Metadata only Temel farmakokinetik ve farmakodinamik prensipler(Güneş Kitabevi, 2022-09-01) GÖREN, MEHMET ZAFER; Gören M. Z.Publication Metadata only Güncel farmakoloji fizyoloji temelinde hasta odaklı yaklaşım(Güneş Kitabevi, 2022-10-01) GÖREN, MEHMET ZAFER; YEGEN, BERRAK; OKUYAN, BETÜL; Şener G. (Editör), Gören M. Z. (Editör), Okuyan B. (Editör), Yegen B. (Editör)Publication Metadata only Gebeliğin ilk trimestırında iohexol maruziyeti, vaka sunumu(2023-07-01) KAŞKAL, MERT; GÖREN, MEHMET ZAFER; Kaşkal M., Gören M. Z.We report a case of a 38-year old pregnant exposed to iohexol who admitted to our teratology information service (TIS). The data was collected by face to face interview and a written consent was taken. She reported that she was given metoprolol for her chest pain and palpitations and she had underwent a cardiac CT investigation with contrast agent iohexol. The patient became aware of her pregnancy in the 6th week after her last menstrual period and admitted to our TIS for the safety of her pregnancy. Metoprolol was used during the 5th and 6th weeks. Radiology consultation was also asked for checking the safety of the dose of radiation she was exposed. During the follow up, she reported that her pregnancy ended as a miscarriage in the 10th week.Publication Open Access Blood pressure and heart rate in aripiprazole once – monthly and paliperidone 1 and 3-month long-acting preparations(2023-05-31) GÖREN, MEHMET ZAFER; Saridogan G. E., GÖREN M. Z.Objective: This study aims to evaluate the blood pressure and heart rates of the patients treated with aripiprazole once-monthly, paliperidone 1-month, and paliperidone 3-month long-acting injections. Patients and Methods: This study was a non-invasive observational study. Subjects using the same long-acting injection preparation for at least four months without skipped injections were assigned to 3 groups according to their treatments. They were screened starting from routine injection day and monthly for four months. Heart rate, systolic blood pressure, and diastolic blood pressure were recorded for each subject. Results: Systolic and diastolic blood pressure among the three treatment groups demonstrated no statistical significance. The heart rate of the paliperidone 3-month group was significantly higher than the aripiprazole once-monthly group. However, the mean heart rate was within the physiological limits. Thus, a clinical significance can hardly be attributed. Conclusion: Aripiprazole once-monthly, paliperidone 1-month, and paliperidone 3-month long-acting injections are non-inferior regarding heart rate, systolic and diastolic blood pressure during the maintenance treatment. Keywords: Long-acting antipsychotic, Hypertension tachycardia, Schizophrenia, Maintenance treatmentPublication Metadata only Renal pathologies and mesalazine use in pregnancy(2022-07-01) KAŞKAL, MERT; GÖREN, MEHMET ZAFER; Vizdiklar C., KAŞKAL M., GÖREN M. Z.